WebFeb 10, 2024 · Cutaneous squamous cell carcinoma (CSCC) represents about 20–25% of non-melanoma skin cancer. 1, 2 Although the incidence of CSCC is not well documented, some evidence has shown a rise in incidence by 3% to 7% per year in most countries. 3, 4 The incidence in Italy is not well defined due to the lack of updated national data 1, 5, 6 … WebOct 6, 2024 · The decision is based on a combined analysis of data from the phase II EMPOWER-CSCC-1 trial and 2 advanced CSCC expansion cohorts from a phase I trial. The 108-patient combined analysis included ...
Key clinical-trial evidence for cemiplimab DermNet
WebEMPOWER-CSCC-1 is an open-label, non-randomised, multicentre, international phase II study including 193 patients with advanced CSCC. Patients were assigned to cemiplimab 3 mg/kg every two weeks (Q2W, … WebApr 26, 2024 · The [phase 2] EMPOWER-CSCC 1 [NCT02760498] trial that was done in 3 [adult patients] groups [led to the approval for this patient population]. Group 1 was patients with metastatic [disease] including nodal metastases or distant metastases. Group 2 was patients with locally advanced disease. And then Group 3 was patients with metastatic … exactly catch
Sanofi : Libtayo ® (cemiplimab) approved for advanced …
WebJul 3, 2024 · Patients in the EMPOWER-CSCC-1 trial received cemiplimab intravenously at 3 mg/kg every 2 weeks for up to 96 weeks. Patients who had disease progression during follow-up had the option for retreatment. Prior anti PD-1/PD-L1 therapy was not allowed. Among the patients with locally advanced disease, the median age was 74 years (range, … WebJun 17, 2024 · EMPOWER-1: A Multi-site Clinical Cohort Study to Reduce Health Inequality: Identifying Ethnic Disparities in Treatment Failures for Medicines Prescribed to Treat Diseases That Cause Significant Mortality and Morbidity in the UK Population: Actual Study Start Date : February 1, 2024: Estimated Primary Completion Date : February 1, … WebOct 21, 2024 · Oct 21, 2024. Glenn J. Hanna, MD, Dana-Farber Cancer Institute. Dr Hanna comments on updated efficacy and safety data of the EMPOWER-CSCC-1 trial that was recently discussed at the annual … exactly chiropractic